drugset / Trial / NCT01145950

Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®

NCT01145950

Phase 1 Completed 36 enrolled LG Life Sciences
RandomizedCrossoverDouble-blind

Summary

To compare the pharmacokinetic characteristic of LBEC0101 25mg with the active comparator, Enbrel® 25 mg.

Timeline

Start
2010-06
Primary completion
2010-11
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg Subcutaneous

Indications

No indication recorded.